Tag: $Kenvue Inc

Kenvue (NYSE:KVUE) stock fell 5.5% in pre-market trading Monday following a Washington Post report that the Trump administration plans to announce concerns about a potential link between Tylenol’s active ingredient and autism risk.

Kenvue’s (KVUE.N), CEO and board member Thibaut Mongon has stepped down, it said on Monday, in the second big executive change at the consumer health company amid push by activist investors to boost performance.

Shares of Kenvue Inc. KVUE jumped 3.4% in premarket trading Tuesday, after the parent of consumer health brands including Band-Aid, Tylenol and Listerine reported second-quarter earnings that beat expectations, boosted by productivity gains and higher pricing.

Kenvue  will cut 4% of its global workforce amid investments to grow its key brands, the Tylenol and Band-Aid maker said on Tuesday, as it topped beat Wall Street estimates for first-quarter profit.

Kenvue Inc.’s stock fell 2.6% early Thursday, after the consumer-health business spun out from Johnson & Johnson last year missed revenue estimates for the fourth quarter and offered soft guidance for 2024.

Shares of Tylenol maker Kenvue Inc. gained more than 5% premarket on Tuesday after a federal court judge in New York ruled that plaintiffs’ expert testimony will be blocked in a case involving product-liability claims against the manufacturers of Tylenol and generic acetaminophen.

Kenvue–0.13% will join the S&P 500SPX –0.70% following the completion of Johnson and Johnson JNJ –0.06% ’s exchange offer for Kenvue stock, according to S&P Dow Jones Indices.